Opthea Limited (OPT)

3.6200 -0.1800 (-4.74%) 收市：04:00PM EDT

Opthea Limited

650 Chapel Street
Suite 0403 Level 4
South Yarra, VIC 3141
Australia
61 3 9826 0399
https://opthea.com

版塊: Healthcare
行業: Biotechnology
全職員工: 24

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.	Founder, Chief Innovation Officer & Executive Director	599.73k	無	1975
Ms. Judith J. Robertson B.A., M.B.A.	Chief Commercial Officer	588.59k	無	1961
Ms. Karen Adams CPA	VP of Finance & Company Secretary	305.14k	無	1972
Dr. Frederic Guerard M.S., Pharm.D.	Chief Executive Officer	無	無	1973
Mr. Peter F. Lang M.B.A.	Chief Financial Officer	無	無	1973
Ms. Sarika Gulhar Ph.D.	Executive Director of Human Resources	無	無	無
Dr. Michael Gerometta Ph.D.	Head of Chemistry, Manufacturing & Controls Development	131.74k	無	1965
Mr. Bruno Gagnon BPHARM, M.Sc.	Senior Vice President of Global Clinical Operations	無	無	1969
Dr. Kenneth Sall	Chief Medical Officer	無	無	無
Dr. Fang Li Ph.D.	Senior Vice President of Regulatory Affairs	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 “VEGFR-3”, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

公司管治

截至 2024年5月1日 止，Opthea Limited 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：10；董事會：6；股東權利：10；現金賠償：10。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。